Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in ICI-refractory Gastric Cancer
NCT04948125Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04948125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948125.